
Quarterly report 2025-Q3
added 11-10-2025
Isoray Financial Statements 2011-2026 | ISR
Annual Financial Statements Isoray
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
24.5 M | 10.2 M | 42.6 M | 53.9 M | 115 M | 25.5 M | 36.4 M | 33.6 M | 42.4 M | 75.7 M | 109 M | 21 M | 31.2 M | 25.9 M |
Shares |
64.4 M | 26.8 M | 142 M | 142 M | 67.6 M | 67 M | 55.2 M | 55 M | 55 M | 54.9 M | 42.7 M | 34.4 M | 28.6 M | 25.1 M |
Historical Prices |
0.38 | 0.38 | 0.3 | 0.38 | 1.7 | 0.8 | 0.45 | 0.48 | 0.6 | 0.72 | 1.34 | 0.74 | 0.71 | 0.63 |
Net Income |
-79.3 M | -46.5 M | -7.34 M | -3.85 M | -3.45 M | -5.14 M | -6.7 M | -6.16 M | -4.71 M | -3.68 M | -5.96 M | -3.86 M | -3.49 M | -2.84 M |
Revenue |
- | - | 3.55 M | 5.38 M | 9.68 M | 7.31 M | 5.92 M | 4.76 M | 4.77 M | 4.61 M | 4.22 M | 4.53 M | 5.07 M | 5.24 M |
Cost of Revenue |
- | - | - | 3.13 M | 4.56 M | 4.27 M | 4.08 M | 3.92 M | 4.64 M | - | - | - | - | - |
Gross Profit |
- | - | 817 K | 2.25 M | 5.12 M | 3.05 M | 1.84 M | 838 K | 129 K | 167 K | -196 K | 150 K | 703 K | 1.16 M |
Operating Income |
-90.9 M | -40.9 M | -5.62 M | -3.91 M | -3.48 M | -5.25 M | -6.73 M | -6.31 M | -5.08 M | -4.34 M | -4.59 M | -4.07 M | -3.6 M | -2.96 M |
Interest Expense |
- | - | - | - | - | 2 K | - | - | 950 | 2.21 K | 883 | 7 | - | - |
EBITDA |
-88.6 M | -40 M | -5.48 M | -3.79 M | -3.33 M | -5.09 M | -6.6 M | -6.19 M | -4.5 M | -3.72 M | -3.87 M | -3.33 M | -2.75 M | -2.07 M |
Operating Expenses |
92.3 M | 42.4 M | 5.62 M | 6.16 M | 8.6 M | 8.32 M | 8.57 M | 7.14 M | 5.21 M | 4.5 M | 4.39 M | 4.22 M | 4.3 M | 4.12 M |
General and Administrative Expenses |
26.6 M | 21.1 M | 4.85 M | 3.46 M | 4.57 M | 4.17 M | 4.16 M | 3.92 M | 3.79 M | 2.4 M | 2.49 M | 2.29 M | 2.36 M | 2.42 M |
All numbers in USD currency
Quarterly Income Statement Isoray
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
74.3 M | 74.2 M | 70.7 M | 70.6 M | 66.6 M | 495 M | 28.2 M | 28.1 M | 28 M | 229 M | 142 M | 142 M | 142 M | 142 M | 142 M | 142 M | 142 M | 123 M | 83 M | 68.9 M | 83 M | 68.9 M | 67.4 M | 67.4 M | 67.4 M | 67.4 M | 67.3 M | 66.1 M | 67.3 M | 66.1 K | 55.1 M | 55 M | 55.1 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 55 M | 54.9 M | 54.9 M | 54.9 M | 54.9 M | 38.4 M | 35.9 M | 38.4 M | 35.9 M | 34.6 M | 33.9 M | 34.6 M | 33.9 M | 28.6 M | 26.5 M | 26.4 M | 26.4 M |
Net Income |
-26 M | -21.5 M | - | -15.1 M | -11.7 M | -12.3 M | - | -10.4 M | -11.1 M | -371 K | - | -4.07 M | -2.08 M | -1.35 M | -1.6 M | -2.24 M | -1.6 M | -2.24 M | -868 K | -868 K | -868 K | -713 K | -897 K | -897 K | -897 K | -816 K | -1.41 M | -1.41 M | -1.41 M | -1.51 M | -1.46 M | -1.55 M | -1.46 M | -1.55 M | -1.45 M | -1.5 M | -1.45 M | -1.5 M | -1.31 M | -1.02 M | -1.31 M | -1.02 M | -907 K | -786 K | -907 K | -786 K | -927 K | -1.27 M | -927 K | -1.27 M | -1.15 M | -994 K | -1.15 M | -994 K | -629 K | -1.1 M | -629 K | -1.1 M |
Revenue |
- | - | - | - | - | - | - | 2.18 M | 2.09 M | 2.06 M | - | 1.72 M | 2.5 M | 2.91 M | 2.82 M | 2.56 M | 2.71 M | 2.6 M | 2.36 M | 2.38 M | 2.28 M | 2.88 M | 2.21 M | 2.32 M | 1.92 M | 1.92 M | 1.9 M | 1.56 M | 1.9 M | 1.56 M | 1.54 M | 1.21 M | 1.37 M | 1.28 M | 1.03 M | 1.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | 1.45 M | 1.84 M | 1.58 M | - | 1.3 M | 1.58 M | 1.47 M | 1.6 M | 1.54 M | 3.13 M | 1.24 M | 1.19 M | 1.14 M | 1.19 M | 1.14 M | 1.1 M | 1.08 M | 1.1 M | 1.08 M | 1.14 M | 1.04 M | 1.14 M | 1.04 M | 1 M | 946 K | - | 989 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | 738 K | 248 K | 487 K | - | 414 K | 926 K | 1.44 M | 1.22 M | 1.03 M | 2.25 M | 1.36 M | 1.17 M | 1.25 M | 1.17 M | 1.25 M | 1.11 M | 1.24 M | 1.11 M | 1.24 M | 765 K | 524 K | 765 K | 524 K | 531 K | 265 K | 531 K | 265 K | -1 K | 48 K | -1 K | 48 K | 30 K | 83 K | 26.9 K | 83.5 K | -38 K | -54.8 K | -38 K | -54.8 K | -33.9 K | -77.3 K | -33.9 K | -77.3 K | -159 K | -20.4 K | -159 K | -20.4 K | 199 K | 66.3 K | 199 K | 66.3 K |
Operating Income |
-27.9 M | -24 M | - | -18.6 M | -14.3 M | -13 M | - | -9.75 M | -9.75 M | -9.76 M | - | -4.21 M | -2.11 M | -1.38 M | -1.64 M | -2.27 M | -3.91 M | -766 K | -873 K | -714 K | -873 K | -714 K | -903 K | -836 K | -903 K | -836 K | -1.43 M | -1.52 M | -1.43 M | -1.52 M | -1.47 M | -1.55 M | -1.47 M | -1.55 M | -1.48 M | -1.58 M | -1.48 M | -1.58 M | -1.41 M | -1.09 M | -1.41 M | -1.09 M | -1.02 M | -1.16 M | -1.02 M | -1.16 M | -1.04 M | -1.23 M | -1.04 M | -1.23 M | -1.1 M | -1.12 M | -1.1 M | -1.12 M | -792 K | -1.1 M | -792 K | -1.1 M |
Interest Expense |
- | - | - | - | - | - | - | 14 K | 28 K | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 2 K | - | 2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 950 | 950 | 100 | - | 3.45 K | 3.45 K | 3.45 K | 86 | 741 | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | -12.7 M | - | -9.49 M | -9.5 M | -9.58 M | - | -4.14 M | -2.03 M | -1.3 M | -1.64 M | -2.22 M | -3.79 M | -766 K | -873 K | -680 K | -802 K | -680 K | -903 K | -798 K | -826 K | -798 K | -1.43 M | -1.49 M | -1.36 M | -1.49 M | -1.47 M | -1.53 M | -1.43 M | -1.53 M | -1.48 M | -1.56 M | -1.45 M | -1.58 M | -1.27 M | -954 K | -1.14 M | -954 K | -885 K | -991 K | -715 K | -991 K | -1.04 M | -1.06 M | -695 K | -1.06 M | -1.1 M | -916 K | -711 K | -916 K | -792 K | -886 K | -357 K | -886 K |
Operating Expenses |
28.1 M | 24.3 M | - | 19 M | 14.8 M | 13.3 M | - | 10 M | 10.3 M | 9.99 M | - | 4.62 M | 3.03 M | 2.82 M | 2.86 M | 3.3 M | 6.16 M | 2.13 M | 2.04 M | 1.96 M | 2.04 M | 1.96 M | 2.01 M | 2.07 M | 2.01 M | 2.07 M | 2.19 M | 2.04 M | 2.19 M | 2.04 M | 2 M | 1.82 M | 2 M | 1.82 M | 1.48 M | 1.62 M | 1.48 M | 1.62 M | 1.44 M | 1.17 M | 1.44 M | 1.17 M | 982 K | 1.11 M | 982 K | 1.11 M | 1.01 M | 1.16 M | 1.01 M | 1.16 M | 941 K | 1.1 M | 941 K | 1.1 M | 991 K | 1.17 M | 991 K | 1.17 M |
General and Administrative Expenses |
7.73 M | 7.71 M | - | 6.98 M | 5.51 M | 5.88 M | - | 4.47 M | 4.99 M | 6.66 M | - | 3.11 M | 1.58 M | 1.58 M | 1.62 M | 1.84 M | 3.46 M | 1.18 M | 1.13 M | 1.07 M | 1.13 M | 1.07 M | 1.07 M | 1.1 M | 1.07 M | 1.1 M | 1.1 M | 973 K | 1.1 M | 973 K | 985 K | 841 K | 985 K | 841 K | 880 K | 927 K | 880 K | 927 K | 1.12 M | 752 K | 1.12 M | 752 K | 538 K | 576 K | 538 K | 576 K | 514 K | 651 K | 514 K | 651 K | 470 K | 645 K | 470 K | 645 K | 497 K | 653 K | 497 K | 653 K |
All numbers in USD currency
Main types of financial statements Isoray ISRFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Isoray plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Baxter International
BAX
|
$ 19.57 | 2.46 % | $ 9.98 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 195.21 | 0.6 % | $ 56.2 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 7.92 | -8.39 % | $ 160 M | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Harvard Bioscience
HBIO
|
$ 0.66 | -1.57 % | $ 28 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Repro Med Systems
KRMD
|
$ 5.68 | -2.24 % | $ 259 M | ||
|
Alcon
ALC
|
$ 77.25 | -1.98 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
$ 39.07 | -1.24 % | $ 1.83 B | ||
|
ICU Medical
ICUI
|
$ 141.14 | -1.07 % | $ 3.44 B | ||
|
electroCore
ECOR
|
$ 4.57 | 1.78 % | $ 25.2 K | ||
|
Merit Medical Systems
MMSI
|
$ 86.79 | -1.54 % | $ 5.05 B | ||
|
iRhythm Technologies
IRTC
|
$ 176.54 | -0.51 % | $ 5.51 B | ||
|
AngioDynamics
ANGO
|
$ 12.65 | -1.48 % | $ 517 M | ||
|
The Cooper Companies
COO
|
$ 81.63 | -0.4 % | $ 16.3 B | ||
|
Nephros
NEPH
|
$ 4.85 | -0.72 % | $ 50.4 M | ||
|
Glaukos Corporation
GKOS
|
$ 111.49 | -1.26 % | $ 5.4 B | ||
|
LeMaitre Vascular
LMAT
|
$ 80.65 | -0.56 % | $ 1.81 B | ||
|
Haemonetics Corporation
HAE
|
$ 79.49 | -0.82 % | $ 4 B | ||
|
InfuSystem Holdings
INFU
|
$ 8.73 | -2.68 % | $ 180 M | ||
|
Masimo Corporation
MASI
|
$ 127.37 | -2.07 % | $ 6.79 B | ||
|
Intuitive Surgical
ISRG
|
$ 559.13 | -1.28 % | $ 199 B | ||
|
OraSure Technologies
OSUR
|
$ 2.44 | 1.03 % | $ 182 M | ||
|
Microbot Medical
MBOT
|
$ 2.04 | 2.0 % | $ 20.8 M | ||
|
Milestone Scientific
MLSS
|
$ 0.28 | 1.65 % | $ 22.3 M | ||
|
Stereotaxis
STXS
|
$ 2.29 | -0.43 % | $ 185 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
$ 21.77 | 0.25 % | $ 3.75 B | ||
|
STERIS plc
STE
|
$ 248.73 | -1.89 % | $ 24.5 B | ||
|
Pro-Dex
PDEX
|
$ 37.63 | -2.21 % | $ 124 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 32.4 M | ||
|
Pulse Biosciences
PLSE
|
$ 13.5 | -1.68 % | $ 649 M | ||
|
Utah Medical Products
UTMD
|
$ 55.99 | 0.05 % | $ 203 M | ||
|
ResMed
RMD
|
$ 244.33 | 1.46 % | $ 35.7 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.47 | 0.31 % | $ 2.33 B | ||
|
Repligen Corporation
RGEN
|
$ 165.31 | 0.88 % | $ 9.21 M | ||
|
BioLife Solutions
BLFS
|
$ 24.07 | -0.48 % | $ 1.11 B | ||
|
Retractable Technologies
RVP
|
$ 0.77 | -0.27 % | $ 23.1 M | ||
|
STAAR Surgical Company
STAA
|
$ 23.53 | 1.88 % | $ 1.16 B | ||
|
Teleflex Incorporated
TFX
|
$ 122.01 | -0.06 % | $ 5.71 B | ||
|
West Pharmaceutical Services
WST
|
$ 274.04 | -0.4 % | $ 20 B |